Home / News / Roche Sues Intas Pharma Over Mircera Anaemia Drug Patent

Roche Sues Intas Pharma Over Mircera Anaemia Drug Patent

Swiss co seeks restraint or-der against Intas’ Erypeg used to treat anaemia in kidney disorder
Economic Times 18 Apr 2016 Vikas.Dan- an injectable brand used to treat dekar@timesgroup.com patients with anaemia in chronic kidney-related ailments. Roche has sought an injunc-tion order against the brand launched by Intas, but no deci-sion has been taken yet, people familiar with the matter in legal circles said.
Roche had close to  Mumbai: Swiss biotechnology giant Roche has sued Ahmedabad-based drug maker Intas Pharmaceuticals in Delhi High Court, alleging infringement of its patent rights over Mircera,  $50o million in global sales for its Mircera brand, reports suggest. Intas confirmed to ET about the Mircera case, adding it is con-tending a non-infringing stand on its product.
“We also have strong grounds of invalidation for the enforced patent,” it noted in re-sponse to queries from ET. Roche officials did not comment, saying the case is sub-judice.Intas launched its product under the brand name Erypeg in India at prices to re- tailer ranging from . 4.080 to .11 8,200, depending on the strength of the injection. Roche’s product is priced between 5285 and . io,62iper injec-tion. It recently raised the prices of Mircera, as seen from the la-bels by ET, but this could not be verified with the company.
Roche has been embroiled in various patent litigations in India, the prominent being its case against Cipla for Tarceva, the drug brand used to treat lung cancer. Earlier this year, Roche and Glenmark mutually settled their dispute over the same drug. Global drug makers have for long sparred with their Indian coun-terparts on issues related to pa-tent protection of original brands. On its part, the government has said it is working on a new patent policy that is expected to outline processes to accelerate decisions.

About Abhiram

Profile photo of Abhiram

Check Also

c

Sandoz EGALITY trial result of biosimilar etanercept show equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from …

Leave a Reply

Your email address will not be published. Required fields are marked *